Surat-based Anupam Rasayan India Ltd said it was acquiring upto 74.2 per cent in Bliss GVS Pharma Limited, a Mumbai-based formulations company.

A provider of custom synthesis and specialty chemicals Anupam Rasayan said in a statement it was picking up 43.3-48.2 per cent equity stake, followed by an open offer to the public shareholders of Bliss GVS Pharma Limited, at a reported ₹1,360-plus crore. The purchase has been financed through ₹300 crore through a term loan, it said.

Bliss GVS Pharma Ltd is engaged in the development, manufacturing, marketing, and export of a wide range of dosage forms including suppositories, pessaries, tablets, capsules, syrups, injectables, creams, and ointments.  Established in 1984, it is listed on the NSE and BSE, and has a presence across regulated and semi-regulated international markets, particularly in Africa, Asia, and Latin America, it said. Bliss GVS Pharma has a diversified portfolio of over 150 branded formulations across therapeutic areas such as antimalarial, anti-fungal, anti-bacterial, anti-inflammatory, and women’s healthcare.

Anand Desai, Managing Director, Anupam Rasayan, said the acquisition marks a milestone in building an integrated global life sciences and specialty pharmaceutical platform. “This will strategically strengthen our presence across the pharmaceutical value chain, spanning KSMs (key starting materials) to finished dosage formulations. Bliss GVS Pharma brings well-established capabilities in niche dosage forms, a strong international footprint, differentiated brands, and expertise across multiple therapeutic segments.”

Published on May 23, 2026